A Phase 1 interventional study of C21 and Sodium Nitroprusside in Study Vasodilatory Effects of C21, sponsored by Vicore Pharma AB. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-23.
Sponsored by Vicore Pharma AB · Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.
Subject will be screened for eligibility. Eligible subjects will receive ascending doses of C21 (3, 10, 30, 100, and 200 µg/min through local intra-arterial infusions for 5 min/dose. Forearm blood flow measurements will be performed in both arms during the last 2 minutes of each dose.
Infusions of sodium nitroprusside will be performed as a positive control using the same methodology.
Vicore Pharma AB is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 µg C21 (infusion rate 3 µg/min) 50 µg C21 (infusion rate 10 µg/min) 150 µg C21 (infusion rate 30 µg/min) 500 µg C21 (infusion rate 100 µg/min) 1000 µg C21 (infusion rate 200 µg/min)
Drug: C21
4 µg nitroprusside (infusion rate 0.8 µg/min) 8 µg nitroprusside (infusion rate 1.6 µg/min) 16 µg nitroprusside (infusion rate 3.2 µg/min)
Drug: Sodium Nitroprusside
C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
Also known as: Compund 21
Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control
Also known as: Nipruss
Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21
Percentage change from baseline in forearm blood flow (FBF) in response to increasing intraarterial doses of C21 (3, 10, 30, 100, and 200 μg/min)
Time frame: 85 minutes
Dose-response Curve of C21 on Forearm Blood Flow (FBF)
Geometric mean forearm blood flow (mL/min) by increasing C21 dose (3, 10, 30, 100, and 200 μg/min)
Time frame: 85 min
Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intra-arterial Doses of Sodium Nitroprusside
Percentage change from baseline in forearm blood flow in response to increasing intra-arterial doses of sodium nitroprusside (0.8, 1.6, and 3.2 μg/min)
Time frame: 45 minutes
Frequency of Adverse Events
Total number of adverse events was counted
Time frame: Day 1-7
Number of Mild, Moderate, and Severe Adverse Events
Number of mild, moderate, and severe adverse events was counted
Time frame: Day 1-7
Number of Serious Adverse Events (SAEs)
Number of serious adverse events (SAEs) was counted
Time frame: Day 1-7
Number of Participants With Clinically Significant Changes in Vital Sign Parameters
Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean systolic blood pressure, diastolic blood pressure or pulse rate were counted
Time frame: 5 hours
Number of Participants With Clinically Significant Changes in ECG Parameters
Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean values of the ECG parameters were counted
Time frame: 5 hours
Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters
Participants with Clinically significant changes from baseline (screening ) to the end of treatment (Day 1) in mean clinical chemistry, haematology or coagulation parameters were counted
Time frame: 5 hours
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 5 | 0 |
| Completed | 5 | 0 |
| Not completed | 0 | 0 |
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 5 | 0 |
| Completed | 5 | 0 |
| Not completed | 0 | 0 |
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 5 | 0 |
| Completed | 5 | 0 |
| Not completed | 0 | 0 |
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 5 | 0 |
| Completed | 5 | 0 |
| Not completed | 0 | 0 |
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 5 | 0 |
| Completed | 5 | 0 |
| Not completed | 0 | 0 |
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 0 | 5 |
| Completed | 0 | 5 |
| Not completed | 0 | 0 |
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 0 | 5 |
| Completed | 0 | 5 |
| Not completed | 0 | 0 |
| Milestone | C21 Combined | Positive Control |
|---|---|---|
| Started | 0 | 5 |
| Completed | 0 | 5 |
| Not completed | 0 | 0 |
Percentage change from baseline in forearm blood flow (FBF) in response to increasing intraarterial doses of C21 (3, 10, 30, 100, and 200 μg/min)
| percentage of change from baseline | C21 3 ug/Min | C21 10 ug/Min | C21 30 ug/Min | C21 100 ug/Min | C21 200 ug/Min |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21 | 27.8 ± 24.3 | 17.2 ± 5.5 | 37.0 ± 26.6 | 28.5 ± 22.7 | 60.5 ± 38.3 |
Geometric mean forearm blood flow (mL/min) by increasing C21 dose (3, 10, 30, 100, and 200 μg/min)
| mL/min | C21 3 ug/Min | C21 10 ug/Min | C21 30 ug/Min | C21 100 ug/Min | C21 200 ug/Min |
|---|---|---|---|---|---|
| Dose-response Curve of C21 on Forearm Blood Flow (FBF) | 2.594 ± 43.2 | 2.594 ± 32.4 | 3.231 ± 44.7 | 3.215 ± 38.1 | 3.907 ± 24.5 |
Percentage change from baseline in forearm blood flow in response to increasing intra-arterial doses of sodium nitroprusside (0.8, 1.6, and 3.2 μg/min)
| percentage of change from baseline | Nipruss 0.8 ug/Min | Nipruss 1.6 ug/Min | Nipruss 3.2 ug/Min |
|---|---|---|---|
| Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intra-arterial Doses of Sodium Nitroprusside | 319.8 ± 186.0 | 229.5 ± 73.1 | 319.6 ± 141.4 |
Total number of adverse events was counted
| Number of adverse events | C21 Group | Total |
|---|---|---|
| Frequency of Adverse Events | 3 | 3 |
Number of mild, moderate, and severe adverse events was counted
| Number of events | C21 Group | Total |
|---|---|---|
| Number of mild AEs | 3 | 3 |
| Number of moderate Aes | 0 | 0 |
| Number of severe AEs | 0 | 0 |
Number of serious adverse events (SAEs) was counted
| Number of SAEs | C21 Group | Total |
|---|---|---|
| Number of Serious Adverse Events (SAEs) | 0 | 0 |
Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean systolic blood pressure, diastolic blood pressure or pulse rate were counted
| Participants | C21 Group | Total |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Sign Parameters | 0 | 0 |
Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean values of the ECG parameters were counted
| Participants | C21 Group | Total |
|---|---|---|
| Number of Participants With Clinically Significant Changes in ECG Parameters | 0 | 0 |
Participants with Clinically significant changes from baseline (screening ) to the end of treatment (Day 1) in mean clinical chemistry, haematology or coagulation parameters were counted
| Participants | C21 Group | Total |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters | 0 | 0 |
Collected over Adverse events were recorded from trial start until end-of-trial contact (follow-up), 7 days after trial start. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| C21 Group | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Total | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Event | C21 Group | Total |
|---|---|---|
| Infusion site bruisingGeneral disorders | 1/5 | 1/5 |
| Ligament sprainInjury, poisoning and procedural complications | 1/5 | 1/5 |
| PresyncopeNervous system disorders | 1/5 | 1/5 |
| Age, Continuous(years) | C21 Combined |
|---|---|
| Mean | 29.0 ± 9.2 |
| Sex: Female, Male(Participants) | C21 Combined |
|---|---|
| Female | 0 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | C21 Combined |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | C21 Combined |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Height(cm) | C21 Combined |
|---|---|
| Mean | 180.0 ± 7.1 |
| Weight(kg) | C21 Combined |
|---|---|
| Mean | 86.8 ± 9.1 |
| Body mass index(kg/m2) | C21 Combined |
|---|---|
| Mean | 26.8 ± 2.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in May 2022, 0 months.
Results were first posted in Apr 2025, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Compound 21 · Nitroprusside
Vicore Pharma AB